Key result
A single injection of autologous stromal vascular fraction cells resulted in at least 50% clinical score improvement in 91% of patients with grade 2-4 degenerative osteoarthritis at 12 months.
Why the study?
Does a single injection of autologous stromal vascular fraction cells improve clinical scores in patients with grade 2-4 degenerative osteoarthritis?
Cohort (n=1,128)
Yes
Does a single injection of autologous stromal vascular fraction cells improve clinical scores in patients with grade 2-4 degenerative osteoarthritis?
p-value: p=<0.0001
Autologous stromal vascular fraction cell therapy appears safe and is associated with significant clinical improvement in patients with degenerative osteoarthritis.
Should not change OA practice; leaves open need for RCTs to confirm SVF efficacy.
Objective: Stromal vascular fraction (SVF), containing high amount of stem cells and other regenerative cells, can be easily obtained from loose connective tissue that is associated with adipose tissue. Here we evaluated safety and clinical efficacy of freshly isolated autologous SVF cells in a case control prospective multi-centric non-randomized study in patients with grade 2-4 degenerative osteoarthritis.
No takes yet. Share an insight, caveat, or question.
Michálek et al. (2017) conducted a cohort in Degenerative osteoarthritis (n=1,128). Autologous stromal vascular fraction (SVF) cells was evaluated on At least 50% improvement in Modified KOOS/HOOS Clinical Score at 12 months (p=<0.0001). A single injection of autologous stromal vascular fraction cells resulted in at least 50% clinical score improvement in 91% of patients with grade 2-4 degenerative osteoarthritis at 12 months.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: